Our take
The Lokomat is the most studied robotic gait trainer, and many rehab centers already run one. The company behind it is now in a court-supervised restructuring.1,3
Buyers should treat service and spare parts as the main risk. Hocoma has stopped US sales and routes North American support through a separate address.2
Scores by criterion
Each criterion is defined on our methodology page.
Who uses Hocoma and what it's for
Rehabilitation centers that already run Lokomat systems and need to plan service and upgrades.2,4
Clinics outside the US considering Hocoma devices during the restructuring.2,3
History
Hocoma AG was registered in 1996 in Volketswil near Zurich and is a brand of DIH, which also owns Motek.3,1
DIH reported $62.9 million in revenue for the fiscal year ended March 31, 2025, with the Lokomat accounting for more than 45%, and its auditor raised substantial doubt about its ability to continue as a going concern.4
Restructuring
A provisional debt moratorium was granted on February 10, 2026. On October 9, 2026, the Uster district court granted a definitive six-month moratorium to April 9, 2027, with Transliq AG as administrator, and creditors must file claims by November 30, 2026.3
Hocoma's US site says it has ceased sales activities in the United States and lists separate contacts for device maintenance and patient incident reports.2
Pricing
A 2023 cost study reported that a Slovak rehab center paid EUR321,160 for a Lokomat in 2007 and that the newest Lokomat Pro FreeD Kombi cost EUR881,292 in 2022.5
Annual service, safety inspections and spare parts were billed as a flat yearly fee in that study.5
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where Hocoma wins or loses |
|---|---|---|---|---|
| Hocoma | Lokomat robotic gait trainer and movement therapy devices1 | Lokomat Pro FreeD Kombi about EUR881,292 in 20225 | Definitive debt moratorium to April 9, 20273 | Most-studied gait robot, maker in restructuring |
| Tyromotion | Lexo end-effector gait trainer plus hand, arm and balance devices7 | About EUR150,000 average per device (2017)9 | EUR15.56M revenue in FY to March 20258 | Tyromotion wins on stability and fast setup. Hocoma wins on Lokomat evidence. |
| Wandercraft | Atalante X and Eve self-balancing exoskeletons18 | Not published18 | Devices in more than 700 rehabilitation centers after buying Ekso19 | Wandercraft wins on overground walking and funding. Hocoma wins on installed base. |
| Cyberdyne | Medical HAL wearable robot driven by the wearer's bioelectric signals13 | Not published; mainly rentals and treatment services14 | Approvals or certifications in more than 20 countries20 | Cyberdyne wins on stability and HAL control. Hocoma wins on treadmill-based evidence. |
| Lifeward | ReWalk personal exoskeleton and AlterG anti-gravity systems17 | Medicare fee of $91,032 for a personal exoskeleton16 | Individual users through Medicare and insurers; AlterG in more than 4,000 facilities16 | Lifeward wins on personal exoskeletons. Hocoma wins on clinic gait volume. |
Limits
Hocoma is in a court-supervised debt moratorium until April 9, 2027.3
It has ceased US sales.2
Its parent's auditor raised going-concern doubt.4
What customers say
Where it helps
Existing Lokomat owners outside the US can keep using installed systems while confirming service terms with the administrator.3,2
Research centers that need Lokomat comparability with published studies remain the main fit.5
Where it falls short
New buyers wanting a stable gait robot supplier should look at Tyromotion, Wandercraft or Cyberdyne.
Leadership
Sources
- DIH, Hocoma, accessed November 9, 2026
- Hocoma, US site notice, archived January 22, 2026, accessed November 9, 2026
- Moneyhouse, Hocoma AG commercial register and SHAB notices, accessed November 9, 2026
- DIH Holding US, Form 10-K for fiscal year ended March 31, 2025, accessed November 9, 2026
- Cost Effectiveness and Resource Allocation, Cost-effectiveness of robot-assisted gait training in cerebral palsy, 2023, accessed November 9, 2026
- Tyromotion, Team, accessed November 9, 2026
- Tyromotion, Lexo gait trainer, accessed November 9, 2026
- Researchly, Tyromotion GmbH, accessed November 9, 2026
- Die Gründer, Tyromotion founders, sale process and new CEO, November 2026, accessed November 9, 2026
- Wandercraft, Atalante X, accessed November 1, 2026
- Wandercraft, Eve personal exoskeleton, accessed November 1, 2026
- Wandercraft, Wandercraft acquires Ekso Bionics, accessed November 1, 2026
- Cyberdyne, Medical HAL lower limb type, accessed November 2, 2026
- Cyberdyne, Financial results briefing for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
- Cyberdyne, Consolidated financial results for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
- Lifeward, Form 10-Q for the quarter ended September 30, 2024, accessed November 1, 2026
- Lifeward, Fourth quarter and full year 2025 financial results, accessed November 1, 2026
- Wandercraft, Homepage, accessed November 2, 2026
- IZON, Wandercraft acquires Ekso Bionics to form major exoskeleton player, accessed November 2, 2026
- Cyberdyne, About Cyberdyne, accessed November 3, 2026


